News

Video

HER2 Positive Biliary Tract Cancer: Navigating Treatment Options

Related Videos
Thomas Westbrook, MD, assistant professor, Department of Internal Medicine, Rush University
John K. Lee, MD, PhD, associate professor-in-residence, Division of Hematology/Oncology, Department of Medicine; the Institute for Urologic Oncology, Department of Urology, the David Geffen School of Medicine, UCLA Heath
Tae Min Kim, MD, PhD
Whitney Goldsberry, MD
Syed Abbas Ali, MBBS
Farrukh Awan, MD
Related Content
OST-HER2 in lung-only metastatic osteosarcoma | Image Credit: © 2rogan - stock.adobe.com
January 16th 2025

OST-HER2 Meets Primary End Point of Phase 2b Trial in Lung-Only Metastatic Osteosarcoma

MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD
January 15th 2025

MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD

Alison Schram, MD
January 16th 2025

Zenocutuzumab Addresses High Unmet Need in NRG1-Positive NSCLC and Pancreatic Cancer

Oncology PER® Spectives™: PSMA in Prostate Cancer: Precision Medicine in Imaging & Therapy
January 14th 2025

Oncology PER® Spectives™: PSMA in Prostate Cancer: Precision Medicine in Imaging & Therapy

Brian Brown, PhD
January 15th 2025

Study Identifies How Ovarian Cancer Protects Itself, Paves Way for Improved Immunotherapy Approach

Yousef Zakharia, MD, medical oncologist, vice chair, Genitourinary Malignancy Disease Group, Mayo Clinic Comprehensive Cancer Center; medical director, Experimental Therapeutics Clinic, Mayo Clinic
January 15th 2025

Phase 3 RCC Data Reinforce Efficacy of Standard IO/TKI Doublets Across IMDC Risk Groups